Exelixis has been granted a patent for a novel crystalline solid form of Compound 1, which is useful for treating various types of cancer, including thyroid, prostate, hepatocellular, renal, and non-small cell lung carcinoma. The invention also includes pharmaceutical compositions and processes for making the crystalline solid forms. GlobalData’s report on Exelixis gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Exelixis Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Exelixis, Cancer treatment biomarkers was a key innovation area identified from patents. Exelixis's grant share as of September 2023 was 34%. Grant share is based on the ratio of number of grants to total number of patents.

Crystalline solid form of compound 1

Source: United States Patent and Trademark Office (USPTO). Credit: Exelixis Inc

A recently granted patent (Publication Number: US11760726B2) discloses a crystalline solid form of Compound 1, referred to as Compound 1 Form XXXI. This form is characterized by specific x-ray powder diffraction patterns measured at room temperature.

Claims 2 and 3 describe the x-ray powder diffraction patterns of Compound 1 Form XXXI, with peaks at 5.0, 10.0, 11.9, and 13.0 (° 2?±0.2° 2?) for Claim 2, and peaks at 14.4, 16.1, 19.9, and 23.8 (° 2?±0.2° 2?) for Claim 3.

Claim 4 expands on the x-ray powder diffraction pattern, including additional peaks at 14.4, 16.1, 19.9, 21.4, and 23.8 (° 2?±0.2° 2?).

Claim 5 further adds a peak at 14.3 (° 2?±0.2° 2?) to the x-ray powder diffraction pattern described in Claim 4.

Claim 6 states that Compound 1 Form XXXI's x-ray powder diffraction pattern is substantially in accordance with the pattern shown in FIG. 26.

Moving beyond the crystalline form, Claim 7 introduces a pharmaceutical composition comprising a therapeutically effective dose of Compound 1 Form XXXI and a pharmaceutically acceptable carrier.

Claims 8, 9, 10, and 11 describe different pharmaceutical formulations that include Compound 1 Form XXXI.

In summary, the granted patent discloses a specific crystalline solid form of Compound 1, referred to as Compound 1 Form XXXI. This form is characterized by its x-ray powder diffraction pattern, which includes specific peaks at various angles. The patent also covers pharmaceutical compositions and formulations that incorporate Compound 1 Form XXXI, potentially indicating its use in the development of therapeutic products.

To know more about GlobalData’s detailed insights on Exelixis, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies